Definium Therapeutics Publishes Corporate Presentation Outlining DT120 ODT Clinical Development Pipeline in Mental Health Indications

Definium Therapeutics published a corporate presentation outlining the DT120 ODT (lysergide) clinical development pipeline in mental health indications.

• Definium outlined a late-stage program for DT120 ODT targeting generalized anxiety disorder, major depressive disorder and posttraumatic stress disorder.
• Phase 3 Voyage in GAD met primary and key secondary endpoints; placebo-adjusted HAM-A improvement was 5.4 points at week 12 (p<0.0001).
• Voyage also showed a 7.7-point placebo-adjusted HAM-A improvement at week 1 (p<0.0001), indicating rapid symptom reduction.
• Topline data for Phase 3 Panorama in GAD are expected in September 2026; Phase 3 readouts in MDD are targeted in 2027.
• Safety and delivery model highlighted single-dose sessions with about 6 hours to end-of-session clearance; about a 1.7% serious adverse event rate across studies.